Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades

Table 5

SEREX clones which encode ZRF1 (DNAJC2, MPP11) antigen.

Clone name	Source	Frequency of antibody response in cancer patients sera versus healthy donors sera	Publication
NY-SCLC-6	NCI-H740 and SK-LC-13 cell lines	N/A	Güre et al., PNAS, 2000; 97: 4198–4203 [19]
NY-BR-13	Breast cancer	3/10 BC versus 3/12 HD	Scanlan et al., Cancer Immun 2001: 4–21 [20]. (Ludwig-sun5.unil.ch/CancerImmunomeDB/)
NGO-St-58, 5	Stomach cancer	4/13 SC versus 3/16 HD	Obata et al.   (Ludwig-sun5.unil.ch/CancerImmunomeDB/) [21]
UL-CML-1	K562 cell line from CML patient	7/19 AML, 6/16 CML, 4/10 RCC, 3/6 MM, 3/12 BC, 3/10 OC versus 0/20 HD	Greiner et al., Int. J. Cancer 2003; 106: 224–231 [22].
KY-MBC 29-88-1	Breast cancer	33/120 BC (including 1/10 MBC, 27/87 IDC, 5/23 ILC), 3/22 FA versus 2/50 HD	Present paper

BC: breast cancer patients; HD: healthy donors; SC: stomach cancer; RCC: renal cell carcinoma; MM: metastatic melanoma; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; OC: ovarian carcinoma.